文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

高危前列腺癌NRG肿瘤学试验中晚期肠道与膀胱毒性的危险因素:医生评定毒性的荟萃分析

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities.
PubMed 文献 · Adv Radiat Oncol · 2018-06-07

该荟萃分析纳入3项NRG试验(RTOG 9202、9413、9406)共2432例高危前列腺癌患者,分析社会人口学变量与晚期(放疗开始后>180天)肠道、膀胱及肠道膀胱集群毒性的关联。多因素分析显示,接受前列腺-only放疗+雄激素阻断治疗的患者发生≥2级肠道毒性的风险低于全盆腔放疗+长期雄激素阻断治疗者(HR 0.36,95%CI 0.18-0.73,P=0.0046)。作者结论认为全盆腔放疗+长期雄激素阻断治疗者≥2级肠道毒性更常见,晚期肠道和膀胱毒性不频繁,未来研究需采用当前放疗技术和患者报告结局确认这些发现。

要点

  • 接受前列腺-only放疗+雄激素阻断治疗者≥2级肠道毒性风险低于全盆腔放疗+长期雄激素阻断治疗者(HR 0.36,95%CI 0.18-0.73,P=0.0046)。
  • 全盆腔放疗后无论接受长期或短期雄激素阻断治疗,≥2级肠道或膀胱毒性机会相似。
  • 晚期≥2级肠道和膀胱毒性发生率分别为13%和16%,≥3级分别为2%和3%。

核心结论

  • 接受全盆腔放疗+长期雄激素阻断治疗的高危前列腺癌患者比接受前列腺-only放疗者更可能发生≥2级肠道毒性。
  • 晚期肠道和膀胱毒性不频繁。
  • 未来研究需采用当前放疗技术和患者报告结局确认这些发现。

研究设计与样本

  • 对3项NRG试验(RTOG 9202、RTOG 9413和RTOG 9406)的荟萃分析,这些试验于1992年至2000年入组患者。
  • 共分析2432例高危前列腺癌患者(临床分期T2c-T4b或Gleason评分8-10或前列腺特异性抗原水平>20)。
  • 晚期毒性采用放射治疗肿瘤学组晚期放射损伤量表测量,定义为放疗开始后>180天。
  • 采用Fine-Gray回归模型,控制研究、年龄、卡氏功能状态评分和入组年份后,以0.05为进入标准逐步加入社会人口学变量。

主要发现

  • 患者中大多数为白人(76%),卡氏功能状态评分为90至100(92%),接受全盆腔放疗+雄激素阻断治疗(67%)。
  • 13%和16%的患者分别发生晚期≥2级肠道和膀胱毒性,2%和3%分别发生晚期≥3级肠道和膀胱毒性。
  • 晚期≥2级肠道和膀胱集群毒性见于约1%的患者,晚期≥3级集群毒性见于2例患者(<1%)。
  • 接受前列腺-only放疗+雄激素阻断治疗的患者发生≥2级肠道毒性的风险低于接受全盆腔放疗+长期雄激素阻断治疗者(HR 0.36,95%CI 0.18-0.73,P=0.0046)。
  • 接受前列腺-only放疗+雄激素阻断治疗的患者发生≥2级肠道毒性的风险低于接受全盆腔放疗+短期雄激素阻断治疗者(HR 0.43,95%CI 0.23-0.80,P=0.008)。

关键数值与推荐

  • 高危前列腺癌定义:临床分期T2c-T4b或Gleason评分8-10或前列腺特异性抗原水平>20。
  • 晚期毒性定义:放疗开始后>180天。
  • 毒性分级采用放射治疗肿瘤学组晚期放射损伤量表。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来研究需采用当前放疗技术和患者报告结局确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A meta-analysis of sociodemographic variables and their association with late (>180 days from start of radiation therapy[RT]) bowel, bladder, and clustered bowel and bladder toxicities was conducted in patients with high-risk (clinical stages T2c-T4b or Gleason score 8-10 or prostate-specific antigen level >20) prostate cancer. METHODS AND MATERIALS: Three NRG trials (RTOG 9202, RTOG 9413, and RTOG 9406) that accrued from 1992 to 2000 were used. Late toxicities were measured with the Radiation Therapy Oncology Group Late Radiation Morbidity Scale. After controlling for study, age, Karnofsky Performance Status, and year of accrual, sociodemographic variables were added to the model for each outcome variable of interest in a stepwise fashion using the Fine-Gray regression models with an entry criterion of 0.05. RESULTS: A total of 2432 patients were analyzed of whom most were Caucasian (76%), had a KPS score of 90 to 100 (92%), and received whole-pelvic RT+HT (67%). Of these patients, 13 % and 16% experienced late grade ≥2 bowel and bladder toxicities, respectively, and 2% and 3% experienced late grade ≥3 bowel and bladder toxicities, respectively. Late grade ≥2 clustered bowel and bladder toxicities were seen in approximately 1% of patients and late grade ≥3 clustered toxicities were seen in 2 patients (<1%). The multivariate analysis showed that patients who received prostate-only RT+HT had a lower risk of experiencing grade ≥2 bowel toxicities than those who received whole-pelvic RT+long-term (LT) HT (hazard ratio: 0.36; 95% confidence interval, 0.18-0.73; P = .0046 and hazard ratio: 0.43; 95% confidence interval, 0.23-0.80; P = .008, respectively). Patients who received whole-pelvic RT had similar chances of having grade ≥2 bowel or bladder toxicities no matter whether they received LT or short-term HT. CONCLUSIONS: Patients with high-risk prostate cancer who receive whole-pelvic RT+LT HT are more likely to have a grade ≥2 bowel toxicity than those who receive prostate-only RT. LT bowel and bladder toxicities were infrequent. Future studies will need to confirm these findings utilizing current radiation technology and patient-reported outcomes.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xiao C, Moughan J, Movsas B, et al. Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities. Adv Radiat Oncol. 2018. PMID: 30202809. doi:10.1016/j.adro.2018.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。